| CEO Name | Ian Page |
| Nationality | United Kingdom |
| Net Worth Estimation | $60 million |
Ian Page, CEO of Dechra Pharmaceuticals, has accumulated an estimated net worth of around $60 million USD primarily through long-term executive compensation, equity grants, and Dechra's sustained stock price growth since his appointment. Public disclosures and annual reports detail significant shareholdings, bonuses, and performance incentives contributing to his overall wealth.
Ian Page, CEO of Dechra Pharmaceuticals, has an estimated net worth of $60,000,000, which is 86% of the highest estimated CEO net worth ($70,000,000) in the veterinary business category. His net worth is also 60 times higher than the minimum estimated CEO net worth ($1,000,000) in this sector.
Business Category: Veterinary
Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 70000000 USD
Ian Page Performance in Dechra Pharmaceuticals
Ian Page, CEO of Dechra Pharmaceuticals, demonstrates strategic leadership by driving innovation and global expansion in the veterinary pharmaceutical market. His decisive approach in reallocating resources and pursuing acquisitions has significantly boosted the company's revenue and market share. Under his tenure, Dechra has seen enhanced operational performance and sustained growth, solidifying its position as a key industry player.
Latest News
Dechra Pharmaceuticals appoints Jesper Nordengaard as CEO, marking a new chapter for the global veterinary pharmaceuticals company. Nordengaard, formerly President of North America at Colgate-Palmolive and CEO of Hill's Pet Nutrition, succeeded Ian Page who retired after 23 years; recent company moves include significant acquisitions and leadership expansions aimed at innovation and market growth.
http://www.dechra.com/news
Source: http://www.dechra-us.com/news/2024/may/appointment-of-jesper-nordengaard-as-dechra-limited-ceo